Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective

Canadian Journal of Cardiology

Volumn 20, Issue 6, 2004, Pages 613-618

  Burgess, Ellen D ^a   Carides, George W ^b   Gerth, William C ^c   Marentette, Michael A ^d   Chabot, Isabelle ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b Biostatistics/Research Div Sciences   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Cost savings; Diabetes; Economics; End stage renal disease; Hypertension; Losartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; LOSARTAN; PLACEBO; ANGIOTENSIN RECEPTOR;

ACCOUNTING; ADULT; AGED; ARTICLE; CALCULATION; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DIABETIC NEPHROPATHY; DRUG COST; ECONOMIC EVALUATION; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; COST CONTROL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; ECONOMICS; HEALTH CARE COST; MIDDLE AGED;

ADULT; AGED; CANADA; COST SAVINGS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN;

EID: 2942736957     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995;18:455-64.
2. Molnar M, Wittmann I, Nagy J. Prevalence, course and risk factors of diabetic nephropathy in type 2 diabetes mellitus. Med Sci Monit 2000;6:929-36.
3. Reikes ST. Trends in end-stage renal disease. Epidemiology, morbidity and mortality. Postgrad Med 2000;108:124-31.
4. Ritz E. Nephropathy in type II diabetes. Exp Clin Endocrinol Diabetes 1997;105(Suppl 2):80-2.
5. Percent distribution of end-stage renal disease by treatment type, Canada, 1990 to 1999 (new cases). Canadian Organ Replacement Register/Canadian Institute for Health Information, 2001. (Version current at March 19, 2004).
6. Schaubel DE, Morrison HI, Desmeules M, Parsons DA, Fenton SS. End-stage renal disease in Canada: Prevalence projections to 2005. CMAJ 1999;160:1557-63.
7. Silins J, Fortier L, Mao Y, et al. Mortality rates among patients with end-stage renal disease in Canada, 1981-86. CMAJ 1989;141:677-82.
8. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Slowing the progression of chronic renal insufficiency. CMAJ 2002;166:906-7.
9. Manns BJ, Taub KJ, Donaldson C. Economic evaluation and end-stage renal disease: From basics to bedside. Am J Kidney Dis 2000;36:12-28.
10. Odoni G, Ritz E. Diabetic nephropathy - what have we learned in the last three decades? J Nephrol 1999;12(Suppl 2):S120-4.
11. Narins BE, Narins RG. Clinical feafures and health-care costs of diabetic nephropathy. Diabetes Care 1988;11:833-9.
12. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-42.
13. Prichard SS. The costs of dialysis in Canada. Nephrol Dial Transplant 1997;12(Suppl 1):22-4.
14. Fenton S, Desmeules M, Copleston P, et al. Renal replacement therapy in Canada: A report from the Canadian Organ Replacement Register. Am J Kidney Dis 1995;25:134-50.
15. Doggrell SA. Class benefits of AT(1) antagonists in type 2 diabetes with nephropathy. Expert Opin Pharmacother 2002;3:625-8.
16. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
17. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
18. Brenner BM, Cooper ME, Zeeuw DD, et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-35.
19. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman Hall, 1993.
20. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
21. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996;19:1051-61.
22. Martin M. As number of patients grows, so do critical problems facing MDs who provide dialysis. CMAJ 1996;154:931-3.
23. International Diabetes Federation. Diabetes Atlas 2000. Brussels: International Diabetes Federation, 2000. (Version current at March 19, 2004).
24. deDios C, Ensign J. Type 2 Diabetes. Waltham: Decision Resources, 2001. (Accessed July 24, 2002). Now available at (Version current at March 19, 2004).
25. National Health and Nutrition Examination Survey III. Hyattsville: National Center for Health Statistics, 2002. (Version current at March 19, 2004).
26. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000;23:390-404.
27. FDA Advisory Committee Background Information, NDA 20-386/S-028: COZAAR (losartan potassium), April 12, 2002.